Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Home

aurobindo-pharma

Tag: aurobindo pharma

Read all Latest developments, information and news on and about Aurobindo-pharma - Page 15

Aurobindo Pharma is a pharmaceutical manufacturing company headquartered in Hyderabad manufacturing generic pharmaceuticals and active pharmaceutical ingredients. - Latest Updates

Five firms including Cadila, Aurobindo Pharma in race to buy bankrupt Sterling Biotech

Medical Dialogues Team23 Aug 2021 4:32 PM IST

New Delhi: Aurobindo Pharma, Cadila Healthcare, UPL, ACG Associated Capsules and Gland Celsus Bio Chemicals are the five firms vying to buy bankrupt...

Aurobindo Pharma cancels Rs 420 crore acquisition deal with Cronus Pharma

Ruchika Sharma21 Aug 2021 1:29 PM IST

New Delhi: Aurobindo Pharma Ltd on Friday said its Rs 420-crore deal to acquire 51 per cent stake in Cronus Pharma Specialities India Pvt Ltd (Cronus)...

Aurobindo Pharma to acquire 51 percent stake in veterinary pharma firm Cronus for Rs 420 crore

Medical Dialogues Team13 Aug 2021 2:29 PM IST

New Delhi: Aurobindo Pharma has announced a definitive agreement under which it would subscribe to new equity shares in Cronus Pharma Specialities...

Aurobindo Pharma to channelize efforts for commercializing COVID vaccine

Ruchika Sharma6 Aug 2021 12:11 PM IST

New Delhi: Drug major Aurobindo Pharma is looking to commercialise a COVID-19 vaccine, build a portfolio of biosimilar products, expand API production...

Aurobindo Pharma reports Rs 801.18 crore net profit in Q4

Medical Dialogues Team31 May 2021 9:00 AM IST

"Net profit after JV share, minority interest is not comparable due to Natrol divestment," Aurobindo Pharma said.

Emcure, Glenmark arm, 3 others line up Rs 7000 crore IPOs

Ruchika Sharma28 May 2021 1:00 PM IST

Mumbai: Amidst the raging second wave of the COVID-19 pandemic and many fearing a third wave, the healthcare sector is in the limelight for the...

Sun Pharma, Dr Reddys, 2 others recall products in US

Ruchika Sharma15 March 2021 1:00 PM IST

New Delhi: Leading home grown drug makers Sun Pharma, Dr Reddy's Laboratories, Aurobindo Pharma and Jubilant Pharma are recalling products in the US...

Aurobindo Pharma to invest Rs 5.38 crore each in 2 solar power firms

Ruchika Sharma25 Feb 2021 12:00 PM IST

New Delhi: Aurobindo Pharma on Tuesday said it has inked a pact to acquire 26 per cent stake each in two Hyderabad-based solar power generating...

Aurobindo Pharma secures USFDA approval for Droxidopa Capsules

Ruchika Sharma20 Feb 2021 12:48 PM IST

Hyderabad: Drugmaker, Aurobindo Pharma Limited, has recently announced that the company has received final approval from the US Food & Drug...

Lupin, Aurobindo units recall Oseltamivir Phosphate, Acetaminophen injection in US

Ruchika Sharma15 Feb 2021 1:58 PM IST

New Delhi: US-based units of drug firms Lupin and Aurobindo Pharma are recalling certain products in the American market, as per the latest...

Aurobindo Pharma net profit jumps over 4-fold to Rs 2,946.32 crore in Q3

Ruchika Sharma13 Feb 2021 9:00 AM IST

New Delhi: Drug firm Aurobindo Pharma on Wednesday reported an over four-fold jump in consolidated net profit to Rs 2,946.32 crore for the quarter...

CDSCO Panel asks Aurobindo Pharma to submit revised clinical trial protocol for Covid-19 vaccine candidate

MD Bureau7 Feb 2021 11:00 AM IST

New Delhi: Recommending that the firm should submit Phase II/III Protocol as per the regulatory authority of Brazil, the Central Drugs Standard...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok